IGEM Therapeutics
Immuno-oncology IgE antibodies for treating solid tumors.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
£840k | Grant | ||
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 900 % | (20 %) | (64 %) | 53 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (1538 %) | (162 %) | (450 %) | (989 %) | (1183 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (1366 %) | (123 %) | (416 %) | (972 %) | (1037 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
IGEM Therapeutics, now known as Epsilogen, is a UK-based immuno-oncology company that develops immunoglobulin E (IgE) antibodies for cancer treatment. The company was spun out of King's College London and builds upon the research of Dr. Sophia Karagiannis, a global leader in the field of IgE antibodies. Dr. Tim Wilson, who has over 28 years of experience in the life sciences sector, was appointed CEO in 2017.
The company is pioneering the development of IgE-based therapeutics, believing that the potent immune responses naturally mediated by IgE are well-suited to destroy solid tumors resident in tissue. Pre-clinical data have shown superior efficacy for their IgE antibodies compared to conventional IgG antibodies in various cancer models. Their technology leverages the epsilon constant region of IgE, which has evolved to recruit powerful immune effector cells like macrophages and basophils. The company's lead product candidate, MOv18 IgE, is the first IgE-based drug to have entered clinical trials.
In 2018, IGEM Therapeutics completed a £5 million Series A financing round. The funding was led by Epidarex Capital, with new investors including Alsa Holdings and the UCL Technology Fund, to advance its portfolio of IgE antibody candidates. The business generates revenue through government funding, strategic partnerships, and the future sales of its therapeutic products.
Keywords: IgE antibodies, immuno-oncology, solid tumors, cancer therapeutics, antibody drug candidates, clinical trials, biopharmaceuticals, epsilon constant region, immune effector cells, tumor destruction, King's College London spin-out, Dr. Sophia Karagiannis, MOv18 IgE, Epidarex Capital, Alsa Holdings, UCL Technology Fund